EPHA2 and non-small cell lung carcinoma: Therefore, to develop new treatments for NSCLC, our study aimed to identify novel antibodies targeting EphA2 and incorporate them into CAR, with the potential to develop CAR-T/NK cell immunotherapy a treatment for NSCLC.